ICER

The Institute for Clinical and Economic Review (ICER) is a trusted non-profit organization that evaluates evidence on the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs; develops reports using innovative methods that make it easier to translate evidence into decisions; and, most distinctively, fills a critical gap by creating sustainable initiatives with all health care stakeholders that can align efforts to use evidence to drive improvements in both practice and policy. Through all its work, ICER seeks to play a pivotal role in creating a future in which collaborative efforts to move evidence into action provide a foundation for a more effective, efficient, and just health care system.


ICER Weekly View 05-18-18

From the desk of Mitchell Stein Good morning. Drinking water from a fire hose – that’s the only way to describe trying to follow drug industry news this week. The President’s speech and elaboration from Azar and Gottlieb, approval of Aimovig, Ebola, biohacking and much more. I’m trying to keep […]


ICER Weekly View 05-11-18

From the desk of Mitchell Stein Good morning. The President will talk about prescription drug prices today (Friday). Last night, there was an off-the-record briefing of reporters on what will be included in the speech. We’ll take a look at what to expect in the Inside the Beltway section below […]


ICER Weekly View 05-04-18

From the desk of Mitchell Stein Good morning. First, my apologies for the delay in publishing this morning. Technical difficulties and all that. Second, before we dive into the week’s news let me wish you a Happy Star Wars Day. May the fourth be with you. (May the 4th, may […]


ICER Weekly View 04-27-18

From the desk of Mitchell Stein Good morning. Lots to cover today (isn’t there always), but first a public service announcement: Tomorrow (Saturday 4/28) is a national prescription drug take-back day. I’ve highlighted these in the past, but tomorrow’s promises to get more attention than ever as Google prepares to […]


ICER Weekly View 04-20-18

From the desk of Mitchell Stein Good morning. A busy week. starting with breakthrough lung cancer news out of American Association of Cancer Researchers conference (see Weekly View in-depth for details), news of an upcoming Presidential speech on drug pricing (See Inside the Beltway), and continuing developments in a potential […]


ICER Weekly View 04-13-18

From the desk of Mitchell Stein Good morning. I couldn’t decide how to lead off this morning… Do I write about today’s date? Do I write about how cold it still is? Do I pick out a favorite story to highlight? Since I can’t decide, let’s jump into the news. […]


ICER Weekly View 04-06-18

From the desk of Mitchell Stein Good morning. Before we get to the week’s news, let me tell you a story. Like many, I take a generic statin – my health insurer uses a PBM, and I order this maintenance drug through their mail order pharmacy. The cost of a […]


ICER Weekly View 03-30-18

From the desk of Mitchell Stein Good morning. I can’t help but lead with last night’s news that Walmart and Humana are talking about working more closely together, up to and including a purchase by Walmart of Humana. While reports indicate talks are in preliminary stages, the news caused a flurry […]


ICER Weekly View 03-23-18

From the desk of Mitchell Stein Good morning. We have a budget. Early this morning the Senate voted to approve the Omnibus that the House had approved on Thursday (The President is expected to sign later today). From a health care perspective, the surprises are what’s not included in the […]


ICER Weekly View 03-16-18

From the desk of Mitchell Stein Good morning. Years from now when you look up the phrase “too much news” you’ll find this past week as the case study. True on the national front (cabinet shake-ups, special elections, student protests, the loss of one of the brightest among us), and […]


ICER Weekly View 03-09-18

From the desk of Mitchell Stein Good morning. Do I focus on Gottlieb talking tough on prices, the Express Scripts sale, or the gut-wrenching look at the impact of high drug prices? Or should I make a joke about Maine blaming me for the 18 inches of snow yesterday because […]


ICER Weekly View 03-02-18

From the desk of Mitchell Stein Good morning. I hope everyone subject to the east coast storm stays safe. Here in Maine, I’m marveling at the fact that I’m not supposed to get any snow. There was lots of non-pharmacy news coming out of Washington this week (as always). But […]


ICER Weekly View 02-23-18

From the desk of Mitchell Stein Good morning. As always lots to cover this week. I hope you find all the information I include useful and some of it fun. Today, if you are looking for fun, I point you to the profile of virus hunter C.J. Peters (last item […]


ICER Weekly View 02-16-18

From the desk of Mitchell Stein Good morning. Calling this a busy time for drug news would be like calling Mount Everest a little hill. Following last week’s budget deal, we had a Council on Economic Advisors drug price report and the Administration’s proposed budget. We also had several large […]


ICER Weekly View 02-09-18

From the desk of Mitchell Stein Good morning. The government is back open. What? It was open when you went to bed and you don’t know what I’m talking about? While you were sleeping, the government shut down and then opened back up. No biggie. What is a biggie is […]


ICER Weekly View 02-02-18

From the desk of Mitchell Stein Good morning. Lots going on inside the beltway this week with the State of the Union, the new HHS Secretary was sworn in and the resignation of the CDC Director – don’t worry, but don’t worry, I’ve got you covered. Keep reading all the […]


ICER Weekly View 01-26-18

From the desk of Mitchell Stein Good morning. Government shutdowns, over $20 billion in deals, cost figure controversy new Secretary of HHS, and gene therapy meeting; it’s been a busy year week so let’s get right to it. This morning we’ll take a look at: ICER in the news – Midwest […]


ICER Weekly View 01-19-18

From the desk of Mitchell Stein Good morning. I am fascinated by the group of hospitals banding together to form a non-profit generic drug firm. Will it have an impact? Will the mere threat of its existence serve as a check on prices? Can it address chronic shortages of older […]


ICER Weekly View 01-12-18

From the desk of Mitchell Stein Good morning. This week J.P Morgan took over San Francisco with their annual Healthcare Conference. I’ll devote Weekly View In-depth to coverage of the event. Congress also returned to DC resulting in lots of Beltway news. Here’s today’s full rundown: ICER in the news […]


ICER Weekly View 01-05-18

From the desk of Mitchell Stein Good morning. Happy New Year and welcome back to those who have been on vacation (and thanks to those who stuck with me last week). Just as the new year was ramping up, the East Coast was hit with a storm. Here at Weekly […]